Silvia Caballero
Dr. Silvia Caballero was born in Peru in 1995. She is a microbiologist at Vedanta Biosciences, a biopharmaceutical company specializing in the development of therapies for immune-mediated diseases using bacterial consortia.
Education[edit]
Silvia Caballero received her undergraduate degree in biological sciences from Hunter College. She later earned her doctorate degree from Weill Cornell Medical College in microbiology and immunology.[1]
Career[edit]
When Dr. Caballero was with Memorial Sloan-Kettering Cancer Center in New York, she was able to have to develop lab mice that had the physiology to mimic intestinal colonization by vancomycin--resistant enterococcus and carbapenem-resistant enterobacteriaceae or superbugs. Utilizing bioinformatic tools, she was able to create scenarios for the mouse gut to be free of multi-drug- resistant bacteria.[2]
Silvia Caballero now leads Vedanta's program focused on multidrug-resistant organisms (MDRO), particularly in the decolonization of MDROs and other gut pathogens from the intestine to prevent infections.[3] [4]
Awards[edit]
TIME 100 NEXT List for Innovative Leaders (2019)[5][6]
Bibliography of Research Dr. Cabellero Authored or Coauthored[edit]
- Fifty shades of graft: How to improve the efficacy of faecal microbiota transplantation for decolonization of antibiotic-resistant bacteria[7]
- Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers.[8]
- Microbiota-derived lantibiotic restores resistance against vancomycin-resistant Enterococcus[9]
References[edit]
- ↑ "Vedanta Biosciences' Silvia Caballero, Ph.D., Named to TIME 100 NEXT List for Innovative Leaders". Bloomberg. 13 November 2019.
- ↑ "Silvia Caballero".
- ↑ "Vedanta Biosciences' Silvia Caballero, Ph.D., Named to TIME 100 NEXT List for Innovative Leaders". www.businesswire.com. 2019-11-13. Retrieved 2023-06-26.
- ↑ "Silvia Caballero". TIME.com. 2019-11-12. Retrieved 2023-06-27.
- ↑ "TIME 100 Next 2019: Silvia Caballero".
- ↑ "Vedanta Biosciences' Silvia Caballero, Ph.D., Named to TIME 100 NEXT List for Innovative Leaders". Associated Press. 13 November 2019.
- ↑ Benjamin Davido, Rui Batista, Aurélien Dinh, Pierre de Truchis, E.M. Terveer, Bruce Roberts, Ed J. Kuijper, Silvia Caballero,
- Fifty shades of graft: How to improve the efficacy of faecal microbiota transplantation for decolonization of antibiotic-resistant bacteria,
- International Journal of Antimicrobial Agents,
- Volume 53, Issue 5,
- 2019,
- Pages 553-556,
- ISSN 0924-8579,
- ↑ Dsouza, Melissa & Menon, Rajita & Crossette, Emily & Bhattarai, Shakti & Schneider, Jessica & Kim, Yun-Gi & Reddy, Shilpa & Caballero, Silvia & Felix, Cintia & Cornacchione, Louis & Hendrickson, Jared & Watson, Andrea & Minot, Samuel & Greenfield, Nick & Schopf, Lisa & Szabady, Rose & Patarroyo, Juan & Smith, William & Harrison, Pratibha & Norman, Jason. (2022). Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers. Cell Host & Microbe. 30. 583-598.e8. 10.1016/j.chom.2022.03.016.
- ↑ Kim, Sohn & Becattini, Simone & Moody, Thomas & Shliaha, Pavel & Littmann, Eric & Seok, Ruth & Gjonbalaj, Mergim & Eaton, Vincent & Fontana, Emily & Amoretti, Luigi & Wright, Roberta & Caballero, Silvia & Wang, Zhong-Min & Jung, Hea-Jin & Morjaria, Sejal & Leiner, Ingrid & Qin, Weige & Ramos, Ruben & Cross, Justin & Pamer, Eric. (2019). Microbiota-derived lantibiotic restores resistance against vancomycin-resistant Enterococcus. Nature. 572. 1-5. 10.1038/s41586-019-1501-z.
This article "Silvia Caballero" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Silvia Caballero. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
